Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells

Blood

Volumn 90, Issue 1, 1997, Pages 270-278

  Iwasaki, Hiromichi ^a   Huang, Peng ^a   Keating, Michael J ^a   Plunkett, William ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DNA; FLUDARABINE; GEMCITABINE; HYDROXYUREA; RIBONUCLEOTIDE REDUCTASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; ULTRAVIOLET IRRADIATION;

EID: 0030921076     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.1.270.270_270_278     Document Type: Article

References (66)

1. Graham FL, Whitmore GF: Studies in mouse L-cells on the incorporation of 1-β-D-arabinofuranosylcytosine into DNA and on inhibition of DNA polymerase by 1-β-D-arabinofuranosylcytosine 5′-triphosphate. Cancer Res 30:2636, 1970
2. Kufe DW, Major PP, Egan EM, Beardsley GP: Correlation of cytotoxicity with incorporation of ara-C into DNA. J Biol Chem 255:8997, 1980
3. Major PP, Egan EM, Beardsley GP, Minden MD, Kufe DW: Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA. Proc Nat Acad Sci USA 78: 3253, 1981
4. Huang P, Chubb S, Plunkett W: Termination of DNA synthesis by 9-β-D-arabinofuranosyl-2-fluoroadenine: A mechanism for cytotoxicity. J Biol Chem 265:16617, 1990
5. Spriggs D, Robins G, Mitchell T, Kufe D: Incorporation of 9-β-D-arabinofuranosyl-2-fluoroadenine into HL-60 cellular RNA and DNA. Biochem Pharmacol 247, 1986
6. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W: Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51:6110, 1991
7. Plunkett W, Huang P, Gandhi V: Metabolism and actions of fludarabine phosphate. Sem Oncol 17:3, 1990 (suppl 8)
8. Xie KC, Plunkett W: Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine in human lymphoblastoid cells. Cancer Res 55:2847, 1995
9. Gandhi V, Estey E, Keating MJ, Chucrallah A, Plunkett W: Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: Pharmacokinetic, pharmacodynamic, and molecular interactions. Blood 87:256, 1996
10. Gunji H, Kharbanda S, Kufe D: Induction of internucleosomal DNA fragmentation in human myeloid leukemia cells by 1-β-D-arabinofuranosylcytosine. Cancer Res 51:741, 1991
11. Huang P, Plunkett W: Fludarabine-and gemcitabine-induced apoptosis: Incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 36:181, 1995
12. Huang P, Robertson LE, Wright S, and Plunkelt W: High molecular weight DNA fragmentation: A critical event in nucleoside analog-induced apoptosis in leukemia cells. Clin Cancer Res 1:1005, 1995
13. Rustum Y, Preisler HD: Correlation between leukemia cell retention of 1-β-D-arabinofuranosylcytosine 5′-triphosphate and response to therapy. Cancer Res 39:42, 1979
14. Kantarjian HM, Estey EH, Plunkett W, Keating MJ, Walters RS, Iacoboni S, McCredie KB, Freireich EJ: Phase I-II clinical and pharmacologic study of high-dose cytosine arabinoside in refractory leukemia. Am J Med 81:387, 1986
15. Estey EH, Keating MJ, McCredie KB, Freireich EJ, Plunkett W: Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia. Leukemia 4:95, 1990
16. Preisler HD, Azarnia N, Raza A, Grunwald H, Vogler R, Browman G, Goldberg J, Chervenick P, Miller K, Brennan J: Relationship between the per cent of marrow cells in S phase and the outcome of remission-induction therapy for acute nonlymphocytic leukemia. Br J Haematol 56:399, 1984
17. Keating MJ, O'Brien S, Robertson LE, Kantarjian H, Dimopolous M, McLaughlin P, Cabanillas F, Gregoire V, Yang L-Y, Gandhi V, Estey E, Plunkett W: New initiatives with fludarabine monophosphate in hematologic malignancies. Sem Oncol 20:13, 1993 (suppl 5)
18. Saven A, Piro LD: 2-Chlorodeoxyadenosine: A newer purine analog active in the treatment of indolent lymphoid malignancies. Ann Intern Med 120:784, 1994
19. Tallman MS, Hakimian D: Purine nucleoside analogs: Emerging role in indolent lymphoproliferative disorders. Blood 86:2463, 1995
20. Johnstone AP, Williams GT: Role of DNA breaks and ADP-ribosyl transferase in eukaryotic differentiation demonstrated in human lymphocytes. Nature 300:368, 1982
21. Seto S, Carrera CJ, Kubota M, Wasson DB, Carson DA: Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest 75:377, 1985
22. Greer WL, Kaplan JG: Early nuclear events in lymphocyte proliferation. The role of DNA strand break repair and ASP ribosylation. Exp Cell Res 166:399, 1986
23. Kufe DW, Weichselbaum R, Egan EM, Dahlberg W, Fram RJ: Lethal effects of 1-β-D-arabinofuranosylcytosine incorporation into deoxyribonucleic acid during ultraviolet repair. Mol Pharmacol 25:322, 1984
24. Sandoval A, Consoli U, Plunkett W: Fludarabine-mediated inhibition of nucleotide excision repair induces apoptosis in quiescent human lymphoblasts. Clin Cancer Res 2:1731, 1996
25. Sancar A: DNA excision repair. Ann Rev Biochem 65:43, 1996
26. Wood RD: DNA repair in eukaryotes. Ann Rev Biochem 65:135, 1996
27. Robertson LE, Kantarjian H, O'Brien S, Yang L-Y, Gandhi V, Lerner S, Plunkett W, Keating MJ: Cisplatin, fludarabine, and ara-C (PFA): A regimen for advanced fludarabine-refractory chronic lymphocytic leukemia (CLL). Proc Am Soc Clin Oncol 12:308, 1993
28. Keating MJ, O'Brien S, McLaughlin P, Kantarjian H, Cabanillas F: Fludarabine in combinations in the management of chronic lymphocytic leukemia and low grade lymphoma. Ann Oncol 7:34, 1996 (abstr, suppl 3)
29. Robertson LE, O'Brien S, Kantarjian H, Koller C, Beran M, Andreef M, Lerner S, Keating MJ. Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia. Leukemia 9:943, 1995
30. McLaughlin P, Hagemeister FB, Romaguera JE, Sarris AH, Pate O, Younes A, Swan F, Keating M, Cabanillas F: Fludarabine, mitoxantrone, and dexamethasone: An effective new regimen for indolent lymphoma. J Clin Oncol 14:1262, 1996
31. Child JA, Johnson SAN, Smith GM, Morgan GJ, Johnson PWM, Prentice AG, Thorpe SC: Developing strategies for effective pre-autograft chemotherapy for recurrent/refractory intermediate/ high grade non-Hodgkin's lymphoma. Ann Oncol 7:170, 1996 (suppl 3)
32. Nicander B, Reichard P: Dynamics of pyrimidine deoxynucleoside triphosphate pools in relationship to DNA synthesis in 3T6 mouse tibroblasts. Proc Natl Acad Sci USA 80:1347, 1983
33. Spasokukotskaja T, Sasvari-Szekely M, Taljanidisz J, Staub M: Compartmentation of dCTP pools disappears after hydroxyurea or araC treatment in lymphocytes. FEBS Lett 297:151, 1992
34. Xu YZ, Huang P, Plunkett W: Functional compartmentation of dCTP pools: Preferential utilization of salvaged deoxycytidine for DNA repair in human lymphoblasts. J Biol Chem 270:631, 1995
35. Coverley D, Laskey RA: Regulation of eukaryotic DNA replication. Ann Rev Biochem 63:745, 1994
36. White EL, Shaddix SC, Brockman RW, Bennett LL Jr: Comparison of the actions of 9-β-D-arabinofuranosyl-2-fluoroadenine and 9-β-D-arabinofuranosyladenine on target enzymes from mouse tumor cells. Cancer Res 42:2260, 1982
37. Tseng W-C, Derse E, Cheng Y-C, Brockman TW, Bennett LL Jr: In vitro activity of 9-β-D-arabinofuranosyl-2-fluoroadenine and the biochemical action of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. Mol Pharmacol 21:474, 1982
38. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB. Plunkett W: Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 38:567, 1990
39. Baker CH, Banzon J, Bollinger JM, Stubbe J, Samano V, Robins MJ, Lippert B, Jarvi E, Resvick R: 2′-deoxy-2′-methylenecytidine and 2′-deoxy-2′,2′-difluorocytidine 5′-diphosphates: Potent mechanism-based inhibitors of ribonucleotide reductase. J Med Chem 34:1876, 1991
40. Cheson BD, Bennett JM, Rai KR, Grever MR, Kay NE, Schiffer CA, Oken MM, Keating MJ, Boldt DH, Kempin SJ, Foon KA: Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the National Cancer Institute-sponsored working group. Am J Hematol 29:152, 1988
41. Huang P, Plunkett W: A quantitative assay for fragmented DNA in apoptotic cells. Anal Biochem 207:163, 1992
42. Ball CR, Roberts JJ: Estimation of interstrand DNA cross-linking resulting from mustard gas alkylation of HeLa cells. Chem Biol Interact 4:297, 1971
43. Smith CA, Cooper PK, Hanawalt PC: Measurement of repair replication by equilibrium sedimentation, in Friedberg EC, Hanawalt PC (eds): A Laboratory Manual of Research Procedures, vol 1. New York, NY, Dekker, 1981, p 289
44. Sherman PA, Fyfe JA: Enzymatic assay for deoxyribonucleoside triphosphates using synthetic oligonucleotides as template primers. Anal Biochem 180:222, 1989
45. Ashman CR, Reddy GPV, Davidson RL: Bromodeoxyuridine mutagenesis, ribonucleotide reductase activity, and deoxyribonucleotide pools in hydroxyurea-resistant mutants. Somat Cell Genet 7:751, 1981
46. Shewach DS, Ellero J, Mancini WR, Ensminger WD: Decrease in TTP pools mediated by 5-bromo-2′-deoxyuridine exposure in a human glioblastoma cell line. Biochem Pharmacol 43:1579, 1992
47. Moore EC, Cohen SS: The effects of arabinosylnucleotides on ribonucleotide reduction by and enzyme system from rat tumor. J Biol Chem 242:2116, 1967
48. Gandhi V, Plunkett W: Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res 48:329, 1988
49. Xu YZ, Plunkett W: Modulation of deoxycytidylate deaminase in intact human leukemia cells. Biochem Pharmacol 44:1819, 1992
50. Hiss EA, Preston RJ: The effect of cytosine arabinoside on the frequency of single-strand breaks in DNA of mammalian cells following irradiation or chemical treatment. Biochim Biophys Acta 478:1, 1977
51. Snyder RD, Houten BV, Regan JD: The inhibition of ultraviolet radiation-induced DNA repair in human diploid fibroblasts by arabinofuranosyl nucleosides. Chem Biol Interact 50:1, 1984
52. Plunkett W, Huang P, Searcy C, Gandhi V: Gemcitabine: Preclinical pharmacology and mechanisms of action. Sem Oncol 23:3, 1996 (suppl 10)
53. Datta N, Shewach S, Mitchell BS, Fox IH: Kinetic properties and inhibition of human T lymphoblast deoxycytidine kinase. J Biol Chem 264:9359, 1989
54. Grant S: Biochemical modulation of cytosine arabinoside. Pharmacol Ther 48:29, 1990
55. Gandhi V, Plunkett W: Modulation of arabinosyl nucleoside metabolism by arabinosyl nucleotides in human leukemia cells. Cancer Res 48:329, 1988
56. Gandhi V, Nowak B, Keating MJ, Plunkett W: Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: Implications for combination therapy. Blood 74:2070, 1989
57. Gandhi V, Estey E, Keating MJ, Plunkett W: Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 11:116, 1993
58. Seymour JF, Huang P, Plunkett W, Gandhi V: Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: Implication for a continuous infusion schedule. Clin Cancer Res 2:653, 1996
59. Gandhi V, Plunkett W: Modulatory activity of 2′,2′-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosylnucleosides. Cancer Res 50:3675, 1990
60. Cory JG, Chiba P: Combination chemotherapy directed at the components of nucleoside diphosphate reductase, in Cory JG, Cory AH (eds): Inhibitors of Ribonucleoside Diphosphate Reductase. Tarrytown, NY, Pergamon, 1989, p 245
61. Zhou BS, Hsu N-Y, Pan B-C, Doroshow JH, Yen Y: Overexpression of ribonucleotide reductase in transfected human KB cells increases their resistance to hydroxyurea: M2 but not M1 is sufficient to increase resistance to hydroxyurea in transfected cells. Cancer Res 55:1328, 1995
62. Cheng J, Haas M: Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Mol Cell Biol 10:5502, 1990
63. Park DJ, Nakamura H, Chumakov AM, Said JW, Miller CW, Chen DL, Keoffler HP: Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines. Oncogene 9:1899, 1994
64. Yang L-Y, Li L, Keating MJ, Plunkett W: Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair. Mol Pharmacol 47:1072, 1995
65. Yang L-Y, Li L, Liu L, Keating MJ, Plunkett W: Gemcitabine suppresses the repair of cisplatin adducts in plasmid DNA by extracts of cisplatin-resistant human colon carcinoma cells. Proc Am Assn Cancer Res 36:357, 1995
66. Shewach DS, Reynolds KK, Hertel: Nucleoside specificity of human deoxycytidine kinase. Mol Pharmacol 42:518, 1992